{
    "organizations": [],
    "uuid": "718132d896b8350a0b7fcf6db35a3c7a2559d2f6",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-allergan-says-fda-approves-avycaz/brief-allergan-says-fda-approves-avycaz-for-treating-patients-with-habp-vabp-idUSB8N1KT00I",
    "ord_in_thread": 0,
    "title": "BRIEF-Allergan Says FDA Approves Avycaz For Treating Patients With HABP/VABP",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 1 (Reuters) - Allergan Plc:\n* ALLERGAN - FDA APPROVES AVYCAZ (CEFTAZIDIME & AVIBACTAM) FOR TREATING PATIENTS WITH HOSPITAL-ACQUIRED & VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA\n* ALLERGAN - EXPANDED USE BASED ON RESULTS FROM PHASE 3 STUDY EVALUATING EFFICACY, SAFETY OF AVYCAZ FOR TREATING ADULT PATIENTS WITH HABP/VABP Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-02T05:36:00.000+02:00",
    "crawled": "2018-02-02T13:12:18.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "allergan",
        "plc",
        "allergan",
        "fda",
        "approves",
        "avycaz",
        "ceftazidime",
        "avibactam",
        "treating",
        "patient",
        "bacterial",
        "pneumonia",
        "allergan",
        "expanded",
        "use",
        "based",
        "result",
        "phase",
        "study",
        "evaluating",
        "efficacy",
        "safety",
        "avycaz",
        "treating",
        "adult",
        "patient",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}